Jianhui Wu

1.5k citations
102 papers · 1.3k indexed · h-index 17

Jianhui Wu

96 papers receiving 1.2k citations

Peers

Jianhui Wu
Comparison fields: 5 of 109
  • Cancer Research 298
  • Toxicology 53
  • Immunology and Allergy 68
  • Organic Chemistry 314
  • Molecular Biology 724
Replace Xiaohong Shu with:
Xiaohong Shu China
Lijun Sun United States
Federica Finetti Italy
Yih‐Fung Chen Taiwan
Judit Molnár Hungary
ShangLi Zhang China
Tillmann Cyrus United States
Amir Faisal Pakistan
Kosuke Shimizu Japan
Tingzhong Wang China
Jianhui Wu relative to Xiaohong Shu China Xiaohong Shu's profile →
Citations per field
00.5×1.5×
Xiaohong Shu · 1×
Citations per year

Countries citing papers authored by Jianhui Wu

Since Specialization
Citations

This map shows the geographic impact of Jianhui Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianhui Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianhui Wu more than expected).

Fields of papers citing papers by Jianhui Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianhui Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianhui Wu. The network helps show where Jianhui Wu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jianhui Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jianhui Wu Line = papers co-authored together Jianhui Wu links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20255
2 20250
3 20250
4 20250
5 202312
6 20231
7
Downregulation of RRM2 Attenuates Retroperitoneal Liposarcoma Progression via the Akt/mTOR/4EBP1 Pathway: Clinical, Biological, and Therapeutic Significance
20201
8 20204
9 20201
10 20199
11 20182
12 201842
13 201613
14 2012141
15 20128
16 20127
17 20113
18 201012
19 200987
20 200723

About Jianhui Wu

Jianhui Wu is a scholar working on Cancer Research, Immunology and Allergy and Toxicology, having authored 102 papers that have together received 1.3k indexed citations. Recurring topics across this work include Synthesis and bioactivity of alkaloids (17 papers), Synthesis and Biological Evaluation (11 papers), Cancer therapeutics and mechanisms (9 papers), Cancer-related molecular mechanisms research (9 papers), Antiplatelet Therapy and Cardiovascular Diseases (9 papers), RNA modifications and cancer (8 papers), Synthesis and biological activity (7 papers) and Nanoparticle-Based Drug Delivery (6 papers). The work is most often cited by research in Cancer Research (298 citations), Toxicology (53 citations) and Immunology and Allergy (68 citations). Jianhui Wu has collaborated with scholars based in China, Taiwan and United States. Frequent co-authors include Shiqi Peng, Yuji Wang, Ming Zhao, Yaonan Wang, Jianming Tang, Ming Zhao, Meiqing Zheng, Keduo Qian, Jiawang Liu and Kuo‐Hsiung Lee. Their work appears in journals such as European Journal of Medicinal Chemistry, International Journal of Nanomedicine, MedChemComm, Drug Design Development and Therapy and Bioorganic & Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026